-

Fresenius Kabi Named 2022 Pharmaceutical Supplier Partner of the Year by Vizient

Recognizing superior service, support, reliability, ethics and integrity

original Fresenius Kabi Named 2022 Pharmaceutical Supplier Partner of the Year by Vizient (Graphic: Business Wire)

Fresenius Kabi Named 2022 Pharmaceutical Supplier Partner of the Year by Vizient (Graphic: Business Wire)

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi has been named the 2022 Pharmaceutical Supplier Partner of the Year by Vizient, Inc., the nation’s largest member-driven health care performance improvement company. The recognition was September 19-21 at the 2022 Vizient Connections Summit in Las Vegas.

The Pharmaceutical Supplier Partner of the Year award recognizes suppliers for their superior service, support, reliability, ethics and integrity. This year, Vizient recognized Fresenius Kabi for providing comprehensive contract access and proactively engaging the broader Vizient enterprise, including consulting and Pharmacy Networks, in support of Vizient pharmacy members.

“We are honored to receive the 2022 Pharmaceutical Supplier Partner of the Year award from Vizient. Customer focus is one of our company values and everyone at Fresenius Kabi plays a critical role in supporting Vizient, its members and the patients they serve. This recognition is a testament to the dedication and care our employees demonstrate, regardless of their individual roles,” said Scott Meacham, president, Pharmaceuticals at Fresenius Kabi USA.

Since 2016, Fresenius Kabi has been named the Vizient Pharmaceutical Supplier Partner of the Year three times, received the overall Supplier of the Year award, and was recognized twice as the Vizient Strategic Programs Pharmaceutical Supplier of the Year.

“We are pleased to recognize Fresenius Kabi as this year’s winner of the Pharmaceutical Supplier Partner of the Year award. Their commitment to product quality and to delivering the highest level of service to our members is exemplary. It is evident that the needs of hospitals and patients are at the center of their market strategy,” said Bharat Sundaram, president and chief operating officer for Vizient.

About Fresenius Kabi

Fresenius Kabi (www.fresenius-kabi.com/us) is a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. To learn about U.S. career opportunities at Fresenius Kabi, visit us at http://www.fresenius-kabi.com/us/join-us and follow us on LinkedIn.

Contacts

Joanie Clougherty (614) 717-5741
joan.clougherty@fresenius-kabi.com

Industry:

Fresenius Kabi

Release Versions
English
Hashtags
#FreseniusKabi

Contacts

Joanie Clougherty (614) 717-5741
joan.clougherty@fresenius-kabi.com

Social Media Profiles
Fresenius Kabi USA
Fresenius Kabi USA on YouTube
More News From Fresenius Kabi

Fresenius Kabi and AABB Announce 21st Annual Blood Collectors Week, September 6–12, 2026, Honoring Lifesaving Blood Collection Professionals

LAKE ZURICH, Ill. & BETHESDA, Md.--(BUSINESS WIRE)--Fresenius Kabi and the Association for the Advancement of Blood & Biotherapies (AABB) announced today the launch of the 21st annual Blood Collectors Week, taking place September 6–12, 2026. The annual recognition week celebrates the blood collection professionals whose expertise and dedication help ensure patients across the country have access to safe, high-quality blood and blood components. Blood Collectors Week honors the essential pro...

Fresenius Kabi Launches Generic Sugammadex in Simplist® Ready‑to‑Administer Prefilled Syringe in the U.S.

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, a global healthcare company part of the Fresenius Group, specializing in lifesaving therapies and technologies, today announced the U.S. launch of the FDA‑approved generic Sugammadex Injection. Exclusivity for the branded medicine Bridion® (Merck) expired in July 2026. Fresenius Kabi offers operating room clinicians Sugammadex in a Simplist® ready-to-administer prefilled syringe. Simplist® single-dose, prefilled syringes require no assembly at...

Fresenius Kabi Issues Nationwide Recall of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials Due to Presence of Glass Particles

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of the Fresenius Group, is recalling one lot of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL)20 mL vials to the user level. An internal investigation at the firm found the product to contain glass particles. Risk Statement: The administration of an injectable product containing glass particulates may cause local irritation, pain, or swelling at the infusion site, as well as inflammation of the veins. More se...
Back to Newsroom